Literature DB >> 17974448

[Management of hypertension in children].

A Peco-Antić, I Pejcić.   

Abstract

Treatment of hypertension depends on the cause and severity of hypertension, and wether it is acute or chronic hypertension. In hypertensive emergencies, antihypertensive therapy should be started immediately, even if the cause of the disease is unknown. If the hypertension is present for a short time, blood pressure could be normalized quickly, but if the hypertension is of long or unknown lasting, blood pressure should be normalized gradually, so in that way blood pressure is normalized in 2 to 4 days. In long-term antihypertensive therapy as little as possible drugs should be used, preferably in one or two daily doses. Depending on etiology and pathophysiology of hypertension, we use following drugs, alone or in combination: beta adrenergic blockers (atenolol, propranolol), vasodilators (hydralazine, minoxidil), ACE inhibitors (captopril, enalapril), calcium-channel blockers (nifedipine), diuretics (hydrochlorthiazide, frusemide) and alpha adrenergic blockers (prazosin, phenoxybenzamine). Recently, ACE inhibitors or calcium-channel blockers have been used as the first step in antihypertensive therapy. Surgical treatment includes elimination of tumors (Wilms tu, pheochromocytoma), coarctation of the aorta, revascularisation or percutaneous angioplasty (stenosis of renal artery) and parcial or unilateral nephrectomy in renal scarring. Nonpharmacological management: weight reduction, physical conditioning, dietary modifications etc. accompany pharmacological therapy in children with moderate-to-severe hypertension and are commonly recognized strategies to control mild elevations of blood pressure in children.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 17974448

Source DB:  PubMed          Journal:  Srp Arh Celok Lek        ISSN: 0370-8179            Impact factor:   0.207


  1 in total

1.  Perioperative control of paroxysmal hypertension using esmolol with alpha-blockade in a child with a germline mutated paraganglioma.

Authors:  Amir Babiker; Wejdan Al Hamdan; Sondos Kinani; Yasser Kazzaz; Abdelhadi Habeb; Talal Al Harbi; Mohammed Al Dubayee; M Al Namshan; Abdul Aleem Attasi
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2021-07-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.